Edwards Lifesciences (EW) Q1 2026 Earnings
Edwards Lifesciences reported Q1 2026 revenue of $1.6B (+16.7% YoY), beat analyst consensus of $1.6B by $51.8M. Diluted EPS came in at $0.78 (+21.9% YoY), beat the $0.73 consensus by $0.05. Edwards Lifesciences reports across 4 business segments, led by Transcatheter Aortic Valve Replacement (TAVR), Surgical Structural Heart, and Transcatheter Mitral and Tricuspid Therapies (TMTT).
Financial Snapshot
Trailing eight quarters through Q1 2026
Q1 2026 Earnings FAQ
Common questions about Edwards Lifesciences's Q1 2026 earnings report.
Edwards Lifesciences (EW) reported Q1 2026 earnings on April 23, 2026 after market close.
Edwards Lifesciences reported revenue of $1.6B and diluted EPS of $0.78 for Q1 2026.
Revenue beat the consensus estimate of $1.6B by $51.8M. EPS beat the consensus estimate of $0.73 by $0.05.
Compared to the same quarter a year prior, revenue grew 16.7% from $1.4B a year earlier and diluted EPS grew 21.9% from $0.64.
You can read the 8-K earnings release (0001099800-26-000021) and the 10-Q periodic report (0001099800-26-000026) directly on SEC EDGAR. The filing index links above go to sec.gov.